NCT03679676View on ClinicalTrials.gov

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

April 15, 2025

Study Completion Date

May 2, 2025

Conditions
HypersensitivityFood AllergyHypersensitivity, FoodPeanut HypersensitivityPeanut Allergy
Interventions
DRUG

Omalizumab

Omalizumab is injected every 2 to 4 weeks

DRUG

Dupilumab

"Dupilumab is injected every 2 weeks~combination, or placebo."

OTHER

Placebo

Placebo is injected every 2 to 4 weeks

Trial Locations (3)

90095

University of California Los Angeles (UCLA), Los Angeles

92123

University of California San Diego (UCSD), San Diego

94304

Sean N. Parker Center for Allergy & Asthma Research at Stanford University, Palo Alto

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Food Allergy Research & Education

OTHER

collaborator

Harvard School of Public Health (HSPH)

OTHER

lead

Stanford University

OTHER

NCT03679676 - Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE) | Biotech Hunter | Biotech Hunter